The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,
Psyence Group has completed an export of psilocybin to Psilo Pharma from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner...
Optimi Health Corp.
Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
Revitalist and Wake Network, Inc.
Drug discovery and development company Mindset Pharma has filed for national patents protecting “Family 1” – second-generation psilocybin analogues – in 16 different countries, including South...
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
Optimi Health has launched Blue Serenity – Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.
In a move that aims to provide patients in Canada with the “life-changing opportunity” to receive psilocybin-assisted psychotherapy, TheraPsil and Drug Science are collaborating to launch...
The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).